Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastrointest Oncol. Jan 15, 2018; 10(1): 31-39
Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.31
Table 1 Relationship between clinicopathological characteristics and prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients
Clinicopathological characteristicsAll patients (n = 176)
5-yr OS (%)P value
n%
Sex
Male13174.4%17.4%0.702
Female4525.6%15.8%
Age (yr)
≥ 606838.6%21.8%0.799
< 6010861.4%13.5%
Tumor location
Upper third4324.4%17.7%0.614
Middle third5631.8%19.6%
Lower third6235.2%19.6%
Total158.5%0.0%
Tumor grade (differentiation)
Moderate158.5%19.3%0.241
Poor16191.5%16.5%
Lymphovascular invasion
Yes13979.0%10.3%0.010
No3721.0%30.6%
No. of positive LNs
042.3%37.5%0.174
1-6179.7%31.2%
7-15105.7%0.0%
≥ 1614582.4%15.8%
No. of dissected LNs
≥ 3010660.2%20.6%0.326
< 307039.8%11.6%
Positive LN ratio
≥ 0.83419.3%6.2%0.048
< 0.814280.7%20.5%
Pathologic T stage1
T252.8%40.0%0.420
T32011.4%30.6%
T4a10258.0%12.6%
T4b4927.8%21.2%
Stage1
IIIA52.8%40.0%0.237
IIIB158.5%35.9%
IIIC15688.6%14.0%
Table 2 Multivariate analysis of the prognostic factors for overall survival of T4bN1-3M0/TxN3bM0 gastric cancer patients
Clinicopathological characteristicsP valueOdds ratio95%CI
LowerUpper
Lymphovascular invasion0.011.801.152.8
Node positive rate0.141.360.902.1
Stage0.490.710.341.5
Table 3 Overall survival according to patterns of recurrence in T4bN1-3M0/TxN3bM0 gastric cancer patients after curative resection
Recurrent sitesRecurrent patients (n = 147)
Median OS (mo)5-yr OS(%)P value
n%
Locoregional3322.5%33.928.0%0.001
Peritoneal3825.9%16.00.0%
Distant6745.6%21.314.7%
Table 4 Overall survival of patients with T4bN1-3M0/TxN3bM0 gastric cancer according to distant site of metastasis
Distant metastasis siteRecurrent patients (n = 147)
Median OS (mo)5-yr OS(%)
n%
Liver2617.7%18.315.5%
Lung and pleura128.2%16.80.0%
Bone106.8%30.729.2%
Table 5 Relationship between adjuvant treatment and the prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients
TreatmentnMedian DFS (mo)3-yr DFS (%)P valueMedianOS (mo)5-yr OS (%)P value
Adjuvant chemotherapyYes16412.310.4%0.00025.716.1%0.532
No122.80.0%18.722.2%
ChemotherapyMono- therapy106.70.0%0.58320.30.0%0.661
RegimenDoublet13412.05.3%26.317.4%
Triple2013.05.3%29.718.5%
Adjuvant chemotherapy time≥ 6 mo3923.220.2%0.00040.225.0%0.001
< 6 mo1259.97.3%21.613.4%